Skip Navigation


Rheumatology Advance Access originally published online on March 14, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
42/5/614    most recent
keg176v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moots, R.
Right arrow Articles by Walker, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moots, R.
Right arrow Articles by Walker, D.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 614-616
© 2003 British Society for Rheumatology

Editorial

Biologic therapy in clinical practice: enthusiasm must be tempered by caution

R. Moots1,, A. Taggart2 and D. Walker3

1 University of Liverpool Academic Rheumatology Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL,
2 Department of Rheumatology, Musgrave Park Hospital, Belfast BT9 7JB and
3 Freeman Hospital, Freeman Road, Newcastle upon Tyne NE7 7DN, UK

The first 10% of the full text of this article appears below.

Rheumatoid arthritis (RA) is a major cause of disability and is associated with significant mortality in its own right [1–5]. The effects of therapy with traditional disease-modifying drugs on outcomes have previously left much to be desired. This is not surprising, given the poor understanding of pathological mechanisms underlying this disease at the molecular and cellular levels. A few years ago, however, seminal basic science work identified the importance of the proinflammatory cytokines tumour necrosis factor {alpha} (TNF-{alpha}) and interleukin 1ß (IL-1ß) in RA. These observations rapidly led to the development of agents that inhibited these cytokines and suppressed disease in RA. Drugs current1y licensed for use in RA that inhibit these inflammatory molecules—etanercept, infliximab (TNF-{alpha}) and anakinra (IL-1ß)—have been shown clearly to be effective in reducing disease activity. Indeed, their success in clinical trials is the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. Mpofu, F. Fatima, and R. J. Moots
Anti-TNF-{alpha} therapies: they are all the same (aren't they?)
Rheumatology, March 1, 2005; 44(3): 271 - 273.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Molloy, S. Ramakrishnan, E. Murphy, and M. Barry
Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab
Rheumatology, April 1, 2004; 43(4): 522 - 523.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. A. Wright and A. J. Taggart
Pneumococcal vaccination for RA patients on TNF-{alpha} antagonists
Rheumatology, April 1, 2004; 43(4): 523 - 523.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. Bartram, T. Sheeran, T. Price, and D. Mulherin
Anti-tumour necrosis factor therapy in the West Midlands
Rheumatology, March 1, 2004; 43(3): 400 - 400.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. Estrach, V. E. Abernethy, and J. K. Dawson
Infections and anti-TNF therapy: strategies for screening based on clinical experience
Rheumatology, January 1, 2004; 43(1): 115 - 116.
[Full Text] [PDF]